Genstar Capital and TA Associates Announce Agreement to Merge Compusoft and 2020
30.6.2021 13:00:00 EEST | Business Wire | Press release
Genstar Capital and TA Associates today announced that they have signed a definitive agreement to merge their portfolio companies, Compusoft, a leading international provider of specialized visual Configure, Price, Quote (“vCPQ”) software to key retail and manufacturing industries, and 2020 Technologies (“2020”), a leading provider of specialized computer-aided design (“CAD”), configure, price, quote (“CPQ”) and enterprise solutions dedicated to interior design, space planning and furniture manufacturing industries. The transaction is expected to be completed in the second half of 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005446/en/
Compusoft and 2020 will be combined in a merger of equals to create a leading provider of space planning and manufacturing solutions for the residential and commercial segments. The group will offer an end-to-end suite of planning, design, visualization, configuration, pricing, quoting, ERP and manufacturing solutions to consumers, retailers and suppliers across the kitchen, bathroom, office and residential furniture and commercial and residential windows & doors segments. The expansive global network will be enhanced by local expertise and deep customer relationships developed over decades. An impressive combined workforce will benefit from 65+ years of experience in customer service, catalog content, innovation and technology to bring a best-in-class offering to customers and create a platform for future growth.
Compusoft is a portfolio company of TA Associates, a leading global growth private equity firm that invested in Compusoft in 2018. 2020 is a portfolio company of Genstar Capital, a leading private equity firm focused on investments in targeted segments of the financial services, healthcare, industrials and software industries that recently acquired 2020. The newly-combined company will be majority owned by Genstar and TA.
Mark Stoever, Chief Executive Officer of 2020, said, “The merger of Compusoft and 2020 positions the combined company as a trusted provider whose suite of solutions supports designers, manufacturers and retailers. This is a transformative transaction and the support from Genstar and TA will enable us to invest in the business, new technologies and our people. We look forward to completing the transaction so we can continue to build on our companies’ unwavering commitment to innovation and customer service.”
David Tombre, Chief Executive Officer of Compusoft, said, “We are excited by the opportunity this combination presents to create a leading provider of vCPQ solutions for home and commercial spaces. Given Compusoft’s presence in Europe and 2020’s presence in North and South America, the two businesses are truly complementary. Our priority remains our customer’s success and together we will provide an enhanced offering across support, content, innovation and technology.”
Naveen Wadhera, Managing Director at TA, said, “Since TA’s investment, Compusoft has completed five acquisitions while also realizing sustained and meaningful organic growth. This growth has helped further position Compusoft as a leader, well-suited for what we believe will be a value-enhancing combination with 2020. It has been a privilege to partner with Compusoft during this expansion, and we look forward to working with the combined teams on the next phase of growth.”
Eli Weiss, Managing Director at Genstar Capital, said, “The combination of Compusoft and 2020 is a merger of equals by which there will be a number of benefits. Compusoft and 2020 are leading companies in their respective geographies, and we are confident that this merger will provide opportunities for continued organic and inorganic growth. The company is now better positioned to pursue new global opportunities that will enhance customer service and build on their strong momentum.”
The transaction is subject to customary regulatory approvals and closing conditions. Terms of the transaction were not disclosed.
Goodwin Procter LLP is serving as legal counsel and Alvarez & Marsal as financial and tax advisor to TA. Kirkland & Ellis LLP is serving as legal counsel, Alvarez & Marsal is serving as financial and tax advisor and William Blair is serving as financial advisor to Genstar.
About Compusoft
Compusoft provides visual CPQ solutions that simplify planning, configuration and visualization to power sales processes for the kitchen, bathroom, furniture and window & door industries. Compusoft’s solutions assist customers throughout the sales value-chain from end-customers through to manufacturers and are underpinned by a rich content database. Founded in 1989, Compusoft is headquartered in Sarpsborg, Norway, and serves customers in more than 100 countries with over 600 people in 18 countries across Europe, Asia-Pacific and North America. For more information, please visit www.compusoftgroup.com.
About 2020 Technologies Inc.
2020 helps professional designers, retailers and manufacturers in the interior design and furniture industries capture ideas, inspire innovation and streamline processes. By providing end-to-end solutions and a large collection of manufacturers' catalogs, 2020’s applications enable professional designers and retailers to create kitchens, bathrooms, furniture and commercial offices that look as stunning on the screen as they do in reality. 2020 solutions for furniture and cabinet manufacturers deliver a complete manufacturing operations management capability to run their factories at maximum efficiency. Founded in 1987 and headquartered in Westford, Massachusetts, 2020 employs more than 850 people with direct operations in 11 countries and supports customers in many more locations around the world through a network of value-added resellers. For more information, please visit www.2020spaces.com.
About TA Associates
TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 535 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.
About Genstar Capital
Genstar Capital is a leading private equity firm that has been actively investing in high quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Together with Genstar X and all active funds, Genstar currently has approximately $33 billion of assets under management and targets investments focused on targeted segments of the financial services, healthcare, industrials, and software industries. More information about Genstar Capital can be found at www.gencap.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005446/en/
Contact information
For Compusoft
Divesh Nagarajan
+44-7400015239
divesh.nagarajan@compusoftgroup.com
For 2020 Technologies
Karen Curtis
+1-774-215-6916
karen.curtis@2020spaces.com
For TA Associates
Marcia O’Carroll
TA Associates
+ 1-617-574-6796
mocarroll@ta.com
Philip Nunes
BackBay Communications
+ 1-617-391-0792
phil.nunes@backbaycommunications.com
Amisha Mehta
BackBay Communications
+44 203 475 7551
amisha.mehta@backbaycommunications.com
For Genstar Capital
Chris Tofalli
Chris Tofalli Public Relations
914-834-4334
chris@tofallipr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
